title: Monoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigs.
abstract: Monoclonal antibodies (MAbs) are currently a promising treatment strategy against Ebola virus infection. This study combined MAbs with an adenovirus-vectored interferon (DEF201) to evaluate the efficacy in guinea pigs and extend the treatment window obtained with MAbs alone. Initiating the combination therapy at 3 days postinfection (d.p.i.) provided 100% survival, a significant improvement over survival with either treatment alone. The administration of DEF201 within 2 d.p.i. permits later MAb use, with protective efficacy observed up to 8 d.p.i.
authors.affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada. xiangguo_qiu@phac-aspc.ga.ca
authors.forename: Xiangguo
authors.initials: X
authors.lastname: Qiu
authors.forename: Gary
authors.initials: G
authors.lastname: Wong
authors.forename: Lisa
authors.initials: L
authors.lastname: Fernando
authors.forename: Jane
authors.initials: J
authors.lastname: Ennis
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Turner
authors.forename: Judie B
authors.initials: JB
authors.lastname: Alimonti
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Yao
authors.forename: Gary P
authors.initials: GP
authors.lastname: Kobinger
mesh_terms: D000256:Adenoviridae; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D029043:Ebolavirus / Q000276:immunology*; D005822:Genetic Vectors / Q000235:genetics; D006168:Guinea Pigs; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy* / Q000276:immunology*; D016898:Interferon-alpha / Q000627:therapeutic use*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000911:Antibodies, Monoclonal; D016898:Interferon-alpha